Can MTRR rs1801394 AG and MTR rs1805087 AG modestly reduce remethylation resilience and raise homocysteine?

The remethylation pathway, governed by methionine synthase (MTR) and methionine synthase reductase (MTRR), is crucial for maintaining cellular health by converting homocysteine back into methionine. Heterozygous variants within this pathway can alter enzyme kinetics and compromise this metabolic clearance.

Mechanistic pathways and alterations

• Enzymatic dysfunction: The MTRR rs1801394 AG variant causes an Ile22Met substitution, reducing methionine synthase reductase activity and limiting the reactivation rate of MTR. Concurrently, the MTR rs1805087 AG variant alters enzyme stability and kinetics, slowing the conversion of homocysteine.
• Folate modulation: Beyond direct enzymatic activity, the MTR rs1805087 AG variant independently modulates nutritional status by reducing serum folate levels and increasing the risk of folate deficiency.

Clinical implications for remethylation resilience

• Synergistic bottleneck: Individually, each heterozygous variant modestly diminishes biochemical resilience. When these variants coexist, they exert an interactive bottleneck effect on remethylation capacity.
• Homocysteine accumulation: Under optimized nutritional conditions, adequate folate and vitamin B12 can frequently compensate for these genetic inefficiencies. However, during nutritional stress or alongside compounding variants like MTHFR C677T, this reduced pathway resilience allows plasma homocysteine to rise even when serum folate and B12 levels appear nominally adequate.

Bottom line

• Bottom line: The MTRR rs1801394 AG and MTR rs1805087 AG variants modestly compromise the biochemical resilience of the remethylation pathway, creating a metabolic vulnerability that can cause plasma homocysteine to rise despite adequate serum folate and vitamin B12 status.